Aptose Biosciences Inc. (APTO) Reaches $3.14 After 6.00% Down Move; PASSUR AEROSPACE (PSSR) SI Decreased By 83.33%

January 27, 2018 - By Clifton Ray

The stock of Aptose Biosciences Inc. (NASDAQ:APTO) is a huge mover today! The stock decreased 7.92% or $0.27 during the last trading session, reaching $3.14. About 968,332 shares traded or 64.38% up from the average. Aptose Biosciences Inc. (NASDAQ:APTO) has declined 60.81% since January 27, 2017 and is downtrending. It has underperformed by 77.51% the S&P500.The move comes after 5 months negative chart setup for the $80.61M company. It was reported on Jan, 27 by Barchart.com. We have $2.95 PT which if reached, will make NASDAQ:APTO worth $4.84 million less.

PASSUR AEROSPACE (OTCMKTS:PSSR) had a decrease of 83.33% in short interest. PSSR’s SI was 100 shares in January as released by FINRA. Its down 83.33% from 600 shares previously. The stock decreased 3.56% or $0.1 during the last trading session, reaching $2.71. About 900 shares traded. PASSUR Aerospace, Inc. (OTCMKTS:PSSR) has 0.00% since January 27, 2017 and is . It has underperformed by 16.70% the S&P500.




PASSUR Aerospace, Inc., a business intelligence company, provides predictive analytics and decision support technology for the aviation industry in the United States and internationally. The company has market cap of $20.86 million. It offers data aggregation and consolidation, information, decision support, predictive analytics, collaborative solutions, and professional services to airlines, airports, governments, and business aviation companies. It currently has negative earnings. The firm offers various solutions for traffic flow management, diversion management, flight predictability, surface management, turn time management, connectivity and collaboration, and aviation fees and charges.

Among 5 analysts covering Aptose Biosciences (NASDAQ:APTO), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Aptose Biosciences has $20 highest and $100 lowest target. $7.21’s average target is 129.62% above currents $3.14 stock price. Aptose Biosciences had 15 analyst reports since August 7, 2015 according to SRatingsIntel. On Friday, August 7 the stock rating was upgraded by Zacks to “Hold”. On Monday, October 30 the stock rating was maintained by H.C. Wainwright with “Buy”. RBC Capital Markets maintained Aptose Biosciences Inc. (NASDAQ:APTO) rating on Wednesday, November 11. RBC Capital Markets has “Outperform” rating and $20 target. H.C. Wainwright maintained the shares of APTO in report on Wednesday, November 15 with “Buy” rating. The firm has “Neutral” rating given on Friday, November 20 by TH Capital. Roth Capital upgraded Aptose Biosciences Inc. (NASDAQ:APTO) on Monday, June 13 to “Buy” rating. H.C. Wainwright maintained it with “Hold” rating and $100 target in Wednesday, August 9 report. H.C. Wainwright upgraded the shares of APTO in report on Thursday, September 7 to “Buy” rating. H.C. Wainwright maintained it with “Buy” rating and $6.0 target in Wednesday, December 13 report. As per Friday, November 20, the company rating was downgraded by Roth Capital.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. The company has market cap of $80.61 million. The Company’s lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. It currently has negative earnings. The firm has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.

Analysts await Aptose Biosciences Inc. (NASDAQ:APTO) to report earnings on March, 27. They expect $-0.14 EPS, up 26.32% or $0.05 from last year’s $-0.19 per share. After $-0.11 actual EPS reported by Aptose Biosciences Inc. for the previous quarter, Wall Street now forecasts 27.27% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: